{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:07Z","timestamp":1793978887616,"version":"4.8.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119251","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:25:08Z","timestamp":1786749908000},"page":"119251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Critical structural insights into selective small-molecule and peptide inhibitors of human urokinase-type plasminogen activator"],"prefix":"10.1016","volume":"319","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5116-6137","authenticated-orcid":false,"given":"Donata","family":"Pluskota-Karwatka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-5383","authenticated-orcid":false,"given":"Dariusz","family":"Wawrzyniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0819-2187","authenticated-orcid":false,"given":"Jakub","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Jaworska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Barciszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119251_bib1","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2026.119251_bib2","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2016.10.018","article-title":"Cell-type-specific chromatin states differentially prime squamous cell carcinoma tumor-initiating cells for epithelial to mesenchymal transition","volume":"20","author":"Latil","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejmech.2026.119251_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10238-025-01868-9","article-title":"Metastatic organotropism in peritoneal metastasis: paget's hypothesis revisited","volume":"26","author":"Kim","year":"2026","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2026.119251_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10555-023-10111-4","article-title":"Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype \u2013 challenges ahead","volume":"42","author":"Welch","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2026.119251_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119251_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.stem.2017.01.007","article-title":"Soil primes the seed: epigenetic landscape drives tumor behavior","volume":"20","author":"Whitson","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejmech.2026.119251_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16233976","article-title":"Targeting epigenetic alterations linked to cancer-associated fibroblast phenotypes in lung cancer","volume":"16","author":"Papavassiliou","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119251_bib9","article-title":"Epigenetic regulation of cancer-associated fibroblast heterogeneity","volume":"1878","author":"Kehrberg","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2026.119251_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119251_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119251_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119251_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.biopha.2012.10.003","article-title":"The urokinase plasminogen activator system in breast cancer invasion and metastasis","volume":"67","author":"Tang","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119251_bib14","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4103\/0366-6999.159355","article-title":"Safety and efficacy of low dosage of urokinase for catheter-directed thrombolysis of deep venous thrombosis","volume":"128","author":"Du","year":"2015","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejmech.2026.119251_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117116","article-title":"Diastereoselective synthesis and biological evaluation of new fluorine-containing \u03b1-aminophosphonates as anticancer agents and scaffold to human urokinase plasminogen activator inhibitors","volume":"283","author":"Ciesielska","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the cancer dependency map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119251_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-017-0742-4","article-title":"Factors involved in cancer metastasis: a better understanding to \u201cseed and soil\u201d hypothesis","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119251_bib18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/med.21308","article-title":"Involvement of urokinase-type plasminogen activator system in cancer: an overview","volume":"34","author":"Mekkawy","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119251_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13058-014-0428-4","article-title":"uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies","volume":"16","author":"Duffy","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119251_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/156800909787314002","article-title":"The urokinase plasminogen activator system: a target for anti-cancer therapy","volume":"9","author":"Ulisse","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2026.119251_bib21","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/s41598-018-37259-2","article-title":"The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer","volume":"9","author":"Banys-Paluchowski","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119251_bib22","article-title":"Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer","volume":"19\u201320","author":"Micalet","year":"2023","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.gastro.2025.07.021","article-title":"Selective urokinase inhibition plus chemotherapy: a novel approach to pancreatic cancer treatment via enhanced antitumor immunity and decreased metastasis","volume":"170","author":"Zahid Hosen","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.119251_bib24","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1021\/acs.molpharmaceut.3c00055","article-title":"Recent advances in targeting the urokinase plasminogen activator with nanotherapeutics","volume":"20","author":"Kumar","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119251_bib25","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms22052721","article-title":"A narrative review on plasminogen activator Inhibitor-1 and its (patho)Physiological role: to target or not to target?","volume":"22","author":"Sillen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119251_bib26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biopha.2018.01.029","article-title":"Diversity and functional evolution of the plasminogen activator system","volume":"98","author":"Jaiswal","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119251_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-020-02239-6","article-title":"Plasminogen activator inhibitor-2(PAI-2) overexpression supportsbladder cancer developmentin PAI-1 knockout mice in N-butyl-N-(4-hydroxybutyl)-nitrosamine- induced bladdercancer mouse model","volume":"18","author":"Furuya","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119251_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365894","article-title":"Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1","volume":"15","author":"Ibrahim","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119251_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications","volume":"8","author":"Mahmood","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119251_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s000180050497","article-title":"The plasminogen activation system in tumor growth, invasion, and metastasis","volume":"57","author":"Andreasen*","year":"2000","journal-title":"CMLS Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.119251_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","article-title":"Multi-stage mechanisms of tumor metastasis and therapeutic strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119251_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","article-title":"Surviving at a distance: organ-specific metastasis","volume":"1","author":"Obenauf","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2026.119251_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","article-title":"Metastasis organotropism: redefining the congenial soil","volume":"49","author":"Gao","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2026.119251_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/1471-2407-14-310","article-title":"Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2026.119251_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818616","article-title":"Modulation of cellular function by the urokinase receptor signalling: a mechanistic view","volume":"10","author":"Alfano","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105179","article-title":"The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)","volume":"299","author":"Torres-Paris","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib37","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.2741\/3488","article-title":"Structure, function and antagonists of urokinase-type plasminogen activator","volume":"14","author":"Vincenza Carriero","year":"2009","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.ejmech.2026.119251_bib38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1121143","article-title":"Structure of human urokinase plasminogen activator in complex with its receptor","volume":"311","author":"Huai","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119251_bib39","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1021\/cr000033x","article-title":"Serine protease mechanism and specificity","volume":"102","author":"Hedstrom","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119251_bib40","article-title":"The crystal structure of human urokinase-type plasminogen activator catalytic domain","volume":"4DVA","author":"Jiang","year":"2012","journal-title":"PDB ID:"},{"key":"10.1016\/j.ejmech.2026.119251_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119251_bib42","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2174\/138161211796718143","article-title":"The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling","volume":"17","author":"Carriero","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2026.119251_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-5521(00)00104-6","article-title":"Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator","volume":"7","author":"Katz","year":"2000","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/jmbi.2000.3966","article-title":"Crystals of the urokinase type plasminogen activator variant \u03b2c-uPA in complex with small molecule inhibitors open the way towards structure-based drug design1","volume":"301","author":"Zeslawska","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106600","article-title":"Synthetic and natural guanidine derivatives as antitumor and antimicrobial agents: a review","volume":"138","author":"Gomes","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113293","article-title":"Antimicrobial drugs bearing guanidine moieties: a review","volume":"216","author":"Kim","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib47","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.1021\/acs.jpcb.9b06130","article-title":"Role of guanidinium-carboxylate ion interaction in enzyme inhibition with implications for drug design","volume":"123","author":"Muttathukattil","year":"2019","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119251_bib48","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1074\/jbc.275.10.7239","article-title":"Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite","volume":"275","author":"Nienaber","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib49","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1073\/pnas.97.10.5113","article-title":"(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase","volume":"97","author":"Sperl","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119251_bib50","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0960-894X(02)00312-8","article-title":"4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors","volume":"12","author":"Spencer","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib51","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1021\/jm700962j","article-title":"Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties","volume":"50","author":"Joossens","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib52","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/jm0499209","article-title":"Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator","volume":"47","author":"Joossens","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0960-894X(01)00701-6","article-title":"Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines","volume":"12","author":"Barber","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib54","doi-asserted-by":"crossref","first-page":"9238","DOI":"10.1021\/acs.jmedchem.5b01171","article-title":"Discovery and SAR of novel and selective inhibitors of urokinase plasminogen activator (uPA) with an Imidazo[1,2-a]pyridine scaffold","volume":"58","author":"Gladysz","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib55","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.bmcl.2004.03.094","article-title":"Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines","volume":"14","author":"Barber","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib56","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1021\/jm061066t","article-title":"Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines","volume":"50","author":"Fish","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib61","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1016\/j.bmcl.2011.09.044","article-title":"Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)","volume":"21","author":"Matthews","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib62","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1021\/acs.jmedchem.8b00838","article-title":"6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer","volume":"61","author":"Buckley","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116116","article-title":"Systematic evaluation of structure\u2013property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride","volume":"37","author":"Buckley","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126753","article-title":"6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease","volume":"29","author":"Buckley","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib57","first-page":"486","article-title":"[diuretics in monotherapy and in combination with other diuretics and nondiuretics in the treatment of hypertension]","volume":"59","author":"Spinar","year":"2013","journal-title":"Vnitr. Lek."},{"key":"10.1016\/j.ejmech.2026.119251_bib58","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.26156","article-title":"Anti-Tumour\/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?","volume":"129","author":"Matthews","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119251_bib59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0014-5793(87)80039-X","article-title":"Amiloride selectively inhibits the urokinase-type plasminogen activator","volume":"214","author":"Vassalli","year":"1987","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.ejmech.2026.119251_bib60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2026.119251_bib65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0360-3016(94)90528-2","article-title":"Effect's of hma, an analog of amiloride, on the thermosensitivity of tumors in vivo","volume":"30","author":"Song","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2026.119251_bib66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/bjc.1994.360","article-title":"Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy","volume":"70","author":"Luo","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119251_bib67","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.bbrc.2007.02.061","article-title":"Identification of acid-sensing ion channels in adenoid cystic carcinomas","volume":"355","author":"Ye","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119251_bib68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2016.02.042","article-title":"Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells","volume":"375","author":"Rowson-Hodel","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119251_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/jm0300072","article-title":"Identification of novel binding interactions in the development of potent, selective 2-Naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-Phenyl amide 6-Substitution","volume":"47","author":"Wendt","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bmcl.2004.10.026","article-title":"Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties","volume":"15","author":"Bruncko","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib71","first-page":"3063","article-title":"Interaction with the S1\u03b2-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors","volume":"14","author":"Wendt","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib72","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0960-894X(01)00102-0","article-title":"Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors","volume":"11","author":"Wilson","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0960-894X(01)00247-5","article-title":"Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors","volume":"11","author":"Subasinghe","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib74","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0960-894X(01)00787-9","article-title":"Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors","volume":"12","author":"Rudolph","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib75","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1021\/jm0100638","article-title":"Development of serine protease inhibitors displaying a multicentered short (<2.3 \u00c5) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa","volume":"44","author":"Verner","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1074-5521(01)00084-9","article-title":"Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets","volume":"8","author":"Katz","year":"2001","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib77","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm010244+","article-title":"Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator","volume":"44","author":"Mackman","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib78","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0960-894X(02)00311-6","article-title":"2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors","volume":"12","author":"Mackman","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib79","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1006\/jmbi.2001.4516","article-title":"A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site","volume":"307","author":"Katz","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-2836(03)00399-1","article-title":"Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors","volume":"329","author":"Katz","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib81","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1535-7163.MCT-06-0520","article-title":"Identification of a novel inhibitor of urokinase-type plasminogen activator","volume":"6","author":"Zhu","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119251_bib82","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.bmcl.2009.08.008","article-title":"Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA)","volume":"19","author":"West","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib83","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1016\/j.bmcl.2018.09.001","article-title":"Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis","volume":"28","author":"Islam","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/jm0495778","article-title":"Fragment-Based lead discovery using X-ray crystallography","volume":"48","author":"Hartshorn","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/jm701359z","article-title":"Fragment-Based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator","volume":"51","author":"Frederickson","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib86","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bmc.2011.12.040","article-title":"Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)","volume":"20","author":"Venkatraj","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib87","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1039\/C6FO01825D","article-title":"A structural mechanism of flavonoids in inhibiting serine proteases","volume":"8","author":"Xue","year":"2017","journal-title":"Food Funct."},{"key":"10.1016\/j.ejmech.2026.119251_bib88","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0969-2126(01)00203-9","article-title":"The crystal structure of the catalytic domain of human urokinase-type plasminogen activator","volume":"3","author":"Spraggon","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.119251_bib89","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/1381612033454649","article-title":"Inhibitors of the proteolytic activity of urokinase type plasminogen activator","volume":"9","author":"Rockway","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2026.119251_bib90","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0969-2126(00)00136-2","article-title":"Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite","volume":"8","author":"Nienaber","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.119251_bib91","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.7150\/ijbs.21597","article-title":"Structural principles in the development of cyclic peptidic enzyme inhibitors","volume":"13","author":"Xu","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119251_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117499","article-title":"A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue","volume":"95","author":"Mazzocato","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib93","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1021\/ja400461h","article-title":"Bicyclic peptide ligands pulled out of cysteine-rich peptide libraries","volume":"135","author":"Chen","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119251_bib94","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2174\/1568026023394209","article-title":"Cyclization strategies in peptide derived drug design","volume":"2","author":"Li","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib95","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cbpa.2016.08.004","article-title":"Computational methods to design cyclic peptides","volume":"34","author":"McHugh","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib96","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/cb200478t","article-title":"Bicyclic peptide inhibitor reveals large contact interface with a protease target","volume":"7","author":"Angelini","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119251_bib97","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0960-894X(01)00815-0","article-title":"4-Amidinobenzylamine-Based inhibitors of urokinase","volume":"12","author":"K\u00fcnzel","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib98","doi-asserted-by":"crossref","first-page":"33613","DOI":"10.1074\/jbc.M314151200","article-title":"Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents","volume":"279","author":"Schweinitz","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib99","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0960-894X(00)00149-9","article-title":"Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors","volume":"10","author":"Tamura","year":"2000","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119251_bib100","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/jm060622g","article-title":"Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position","volume":"49","author":"Joossens","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib101","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1021\/acs.jmedchem.8b01908","article-title":"Suppression of tumor growth and metastases by targeted intervention in urokinase activity with cyclic peptides","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib102","first-page":"110","article-title":"Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes","volume":"59","author":"Gustafsson","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2026.119251_bib103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119251_bib104","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.3390\/pharmaceutics15112619","article-title":"The trends and future prospective of in silico models from the viewpoint of ADME evaluation in drug discovery","volume":"15","author":"Komura","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119251_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119251_bib106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119251_bib107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","article-title":"Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions","volume":"101","author":"Lipinski","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119251_bib108","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1023\/A:1012188625088","article-title":"Polar molecular surface properties predict the intestinal absorption of drugs in humans","volume":"14","author":"Palm","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2026.119251_bib109","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrd4578","article-title":"Mitigating risk in academic preclinical drug discovery","volume":"14","author":"Dahlin","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119251_bib111","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1021\/acs.jmedchem.9b01813","article-title":"Integrating the impact of lipophilicity on potency and pharmacokinetic parameters enables the use of diverse chemical space during small molecule drug optimization","volume":"63","author":"Miller","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119251_bib112","doi-asserted-by":"crossref","first-page":"36441","DOI":"10.1039\/D5RA05472A","article-title":"Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015\u20132025)","volume":"15","author":"Al-Karmalawy","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119251_bib113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/ph14020122","article-title":"The current and potential therapeutic use of metformin-the good old drug","volume":"14","author":"Drzewoski","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119251_bib114","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s00726-014-1838-4","article-title":"Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK\/JNK-mediated NF-\u03baB-dependent pathway that reduces uPA and MMP-9 expression","volume":"46","author":"Hsieh","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejmech.2026.119251_bib115","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1111\/cas.15524","article-title":"Metformin inhibits the proliferation and invasion of ovarian cancer cells by suppressing tripartite motif-containing 37-induced tumor necrosis factor receptor-associated factor 2 ubiquitination","volume":"113","author":"Zheng","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119251_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.620641","article-title":"Metformin: targeting the Metabolo-Epigenetic link in cancer biology","volume":"10","author":"Cuy\u00e0s","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119251_bib117","first-page":"1899","article-title":"Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation","volume":"52","author":"Tang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119251_bib118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.61882\/rbmb.14.1.85","article-title":"Metformin increased histone deacetylases 1, 3, and 8 expressions as epigenetic regulators in type 2 diabetic patients","volume":"14","author":"Izadi","year":"2025","journal-title":"Rbmb.Net"},{"key":"10.1016\/j.ejmech.2026.119251_bib119","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1038\/onc.2016.391","article-title":"Metformin alters DNA methylation genome-wide via the H19\/SAHH axis","volume":"36","author":"Zhong","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119251_bib120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13148-018-0593-x","article-title":"Significantly altered peripheral blood cell DNA methylation profile as a result of immediate effect of metformin use in healthy individuals","volume":"10","author":"Elbere","year":"2018","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.119251_bib121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","article-title":"Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.119251_bib122","first-page":"903","article-title":"Organoid models in oncology: advancing precision cancer therapy and vaccine development","volume":"22","author":"Xiao","year":"2025","journal-title":"Cancer Biol. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:03:50Z","timestamp":1793977430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":122,"alternative-id":["S0223523426006963"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119251","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical structural insights into selective small-molecule and peptide inhibitors of human urokinase-type plasminogen activator","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119251"}}